KOSDAQBiotech & Pharma052260

Hyundai Bioland

₩3,515▲ 1.30%2026-11-18 close
Market Cap
₩105.5B
Turnover
₩100M
Volume
30K
Shares out.
30M
PER
7.7×
PBR
0.7×
EPS
₩453
Dividend Yield
2.02%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩70 per share · Prices as of the 2026-11-18 close

01

Report overview

After the Return to Profit, Earnings Stability Is the Test

Hyundai Bioland has posted quarterly profits through the first three quarters of 2026, but after full-year 2025 net income attributable to controlling shareholders fell to KRW 253 million, the sustainability of earnings is the next test.

  1. 1

    Operating profit and net income attributable to controlling shareholders were both positive in each quarter from the first quarter through the third quarter of 2026.

  2. 2

    After an operating loss of KRW 2.47 billion and a net loss attributable to controlling shareholders of KRW 1.77 billion in the fourth quarter of 2025, the company returned to profit in the first quarter of 2026, and net income attributable to controlling shareholders over the latest four quarters totals KRW 13.6 billion.

  3. 3

    Health functional food distribution sales built around Nestlé Health Science brands reached KRW 20.7 billion in 2024, and the company has outlined a plan to lift them above KRW 100 billion by 2030.

  4. 4

    The debt ratio fell to 22.6% at the end of 2025 from 41.1% in 2024, and operating cash flow in 2025 was KRW 19.5 billion.

  5. 5

    Net income attributable to controlling shareholders fell 95.6% to KRW 253 million in 2025, so year-to-year earnings volatility remains large.

02

Business structure

Hyundai Bioland is a healthcare company built on naturally derived bio-materials, operating in cosmetic ingredients, health functional food materials, medical devices and brand distribution. Its cosmetic ingredients are led by natural moisturizing materials such as hyaluronic acid and Machilus extract.

A brokerage report described its health functional food material portfolio as about 100 products. In medical devices, dental barrier membranes and orthopedic wound dressings are the main items, and production lines for both were doubled in March 2025.

The brand segment is an exclusive domestic distribution business for Nestlé Health Science health supplement brands, and according to the Hyundai Department Store Group, health functional food distribution sales were KRW 20.7 billion in 2024.

Cosmetic and health food material businesses accounted for 64.1% of revenue in the first half of 2025, and cosmetic materials alone were 42.2% in the second quarter of 2025. Customers are mainly domestic cosmetics brands and ODM makers, while overseas sales go through distributors to global cosmetics companies.

A brokerage report assessed the company as the number one player in the domestic natural cosmetic materials market with a 25-30% share. The same report noted an operating margin of about 30% in the medical device business. The company is an affiliate of the Hyundai Department Store Group, where it leads the group's healthcare push.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩35.5B₩4.7B13.3%
2025Q4₩26.7B-₩2.5B−9.3%
2026Q1₩38.2B₩5.2B13.6%
2026Q2₩40.3B₩7B17.5%
2026Q3₩37.8B₩6B16.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩99.2B₩9.1B₩4.8B9.1%3.7%36.2%
2023₩101.7B₩7.1B₩8.1B7.0%5.9%35.4%
2024₩119.5B₩16.4B₩5.7B13.7%4.1%41.1%
2025₩130.5B₩12.7B₩300M9.7%0.2%22.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 99.2 billion in 2022 to KRW 101.7 billion in 2023 (up 2.6% year on year), KRW 119.5 billion in 2024 (up 17.5%) and KRW 130.5 billion in 2025 (up 9.2%), a three-year run of gains from 2023 through 2025, with 2025 the largest year of 2022 to 2025.

Reporting tied the 2024 sales growth to the Nestlé product distribution business, whose sales reached KRW 15.3 billion in the first nine months of 2024.

Operating profit was KRW 9.05 billion in 2022, KRW 7.08 billion in 2023 (down 21.8%), KRW 16.4 billion in 2024 (up 131.0%) and KRW 12.7 billion in 2025 (down 22.3%), making 2024 the largest year and 2023 the smallest of 2022 to 2025.

Operating margin was 9.1%, 7.0%, 13.7% and 9.7% in the four years, peaking in 2024 before falling.

Net income attributable to controlling shareholders was KRW 4.76 billion in 2022, rose to KRW 8.06 billion in 2023 (up 69.1%), then fell to KRW 5.7 billion in 2024 (down 29.2%) and KRW 253 million in 2025 (down 95.6%), declining for two straight years from 2024 through 2025.

Reporting attributed the 2024 decline partly to a base effect from a KRW 2.1 billion gain on disposal of property and a KRW 1.5 billion impairment reversal in 2023, plus a property impairment loss in 2024.

In 2025, operating profit of KRW 12.7 billion contrasted with net income attributable to controlling shareholders of KRW 253 million, widening the gap between the operating and net income levels; net income including non-controlling interests was also KRW 253 million.

Operating cash flow was KRW 11.3 billion in 2022, KRW 5.59 billion in 2023, KRW 4.6 billion in 2024 and KRW 19.5 billion in 2025. At the end of 2025, total liabilities were KRW 30.7 billion and total equity was KRW 136.1 billion, with a debt ratio of 22.6%, down from 41.1% in 2024.

Quarterly, the fourth quarter of 2025 brought revenue of KRW 26.7 billion (down 24.7% from the prior quarter), an operating loss of KRW 2.47 billion and a net loss attributable to controlling shareholders of KRW 1.77 billion.

The first quarter of 2026 returned to profit with revenue of KRW 38.2 billion (up 43.1% from the prior quarter), operating profit of KRW 5.19 billion and net income attributable to controlling shareholders of KRW 5.21 billion.

The second quarter of 2026 recorded revenue of KRW 40.3 billion, operating profit of KRW 7.04 billion (up 35.7% from the prior quarter) and net income attributable to controlling shareholders of KRW 5.96 billion (up 14.4%).

The third quarter of 2026 recorded revenue of KRW 37.8 billion (down 6.2% from the prior quarter, up 6.5% year on year), operating profit of KRW 6.03 billion (down 14.3% from the prior quarter, up 28.0% year on year) and net income attributable to controlling shareholders of KRW 4.19 billion (down 29.8% from the prior quarter, up 6.3% year on year). Net income attributable to controlling shareholders over the latest four quarters totals KRW 13.6 billion.

05

Industry analysis

Demand for cosmetic ingredients is shaped by a shift away from animal-derived materials and tighter environmental regulation. The company says it is concentrating on natural material development and R&D to supply higher-value products to global customers.

Health functional food demand is widely viewed as growing on aging populations and rising health awareness. A 2025 brokerage analysis put the company at number one in the domestic natural cosmetic materials market with a 25-30% share.

The same analysis argued that customers able to source diverse natural ingredients from one supplier are likely to seek partnerships with the company. A brokerage report judged the medical device segment to be in excess demand, and the company began expanding production capacity for the segment in March 2025.

The company describes its health food distribution business as aimed at demand for premium health functional foods in Korea. Demand shifts tied to the cosmetics industry cycle can be tracked through customer order flows.

On competition, the company is widening overseas customer ties on the strength of its natural ingredient expertise and international certifications. Since joining the Hyundai Department Store Group, healthcare has become a growth axis for the group.

06

Outlook

The company has outlined a plan to lift health functional food distribution sales above KRW 100 billion by 2030, according to a June 2025 report. Sales in that business were KRW 20.7 billion in 2024, so reaching the target requires sustained large annual growth from that base.

Brand segment sales expanded from KRW 6.3 billion in the first quarter of 2025 to KRW 8.5 billion in the second quarter. A brokerage view reported in 2025 put the annual breakeven point of the brand business at around KRW 35.0 billion to KRW 40.0 billion.

For medical devices, the production lines for dental barrier membranes and orthopedic wound dressings were doubled in March 2025, with full operation planned for the second half after yield stabilization.

A company official said production and deliveries of products skipped during the expansion are resuming and that the company is pushing for additional sales and orders.

The Chinese subsidiary posted an operating loss of about KRW 6.0 billion in 2023, and the company decided at the end of 2024 to sell it to a local company, SeeBiotech. First-half 2026 revenue rose 14.9% year on year, operating profit rose 16.8%, and net income turned to profit, according to FnGuide's company summary.

The company has said it will continue shareholder return initiatives, including a medium- to long-term dividend policy.

07

Valuation

PER
7.7×
PBR
0.7×
ROE
9.5%
EPS
₩453
BPS
₩4,991
Dividend per share
₩70

The share price currently sits below 1 times net asset value, meaning the stock trades under book value per share, which reads against total equity of KRW 136.1 billion and the level of earnings.

Net income attributable to controlling shareholders was only KRW 253 million for full-year 2025, so annual earnings multiples carried little meaning that year.

Net income attributable to controlling shareholders over the latest four quarters totals KRW 13.6 billion, which shifts the reading of multiples toward recent quarterly trends. Reporting said the consolidated payout ratio rose to 36% on the 2024 year-end dividend.

A low multiple relative to net assets sits alongside the 2025 earnings decline, so the number of consecutive profitable quarters in 2026 becomes the reference point for interpreting the multiple. Comparisons with past trading ranges need to be checked alongside the share price trend.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Growth in brand distribution sales

Exclusive domestic distribution of Nestlé Health Science products lifted health functional food distribution sales to KRW 20.7 billion in 2024, and sales reached KRW 6.3 billion in the first quarter of 2025, up 186% year on year, according to a June 2025 company report.

The company has set a target of more than KRW 100 billion in these sales by 2030. The company says the business has also contributed to overall earnings improvement.

Recovery in quarterly profit

Operating profit moved from an operating loss of KRW 2.47 billion in the fourth quarter of 2025 to KRW 5.19 billion in the first quarter of 2026, then KRW 7.04 billion in the second quarter and KRW 6.03 billion in the third. Third-quarter operating profit rose 28.0% year on year.

Stronger financial structure

Total liabilities at the end of 2025 were KRW 30.7 billion against total equity of KRW 136.1 billion, a debt ratio of 22.6%, down from 41.1% at the end of 2024. Operating cash flow rose to KRW 19.5 billion in 2025 from KRW 4.6 billion in 2024. The larger financial cushion is cited as a base for business investment and shareholder returns.

09

Bear factors

Volatility in annual earnings

Operating margin moved sharply, at 9.1% in 2022, 7.0% in 2023, 13.7% in 2024 and 9.7% in 2025. Net income attributable to controlling shareholders fell 95.6% to KRW 253 million in 2025.

The gap between operating profit and net income is wide, and in past years impairment losses and disposal gains moved net income significantly.

Breakeven burden in brand business

The brand business has to clear its annual breakeven point before it adds to profit, which is a burden. Quarterly sales were KRW 6.3 billion in the first quarter of 2025 and KRW 8.5 billion in the second, so how quickly the business reaches that level is the open question. Profit contribution may differ from sales growth depending on the margin structure.

Fourth-quarter loss and overseas exit

In the fourth quarter of 2025, revenue of KRW 26.7 billion turned into an operating loss of KRW 2.47 billion and a net loss attributable to controlling shareholders of KRW 1.77 billion. The quarter shows how quickly quarterly results can swing on one-off items.

The Chinese subsidiary posted an operating loss of about KRW 6.0 billion in 2023, and the sale decided at the end of 2024 may still carry profit or loss effects.

10

Risk factors

Dependence on brand distribution

Growth in domestic health food distribution depends on the exclusive distribution partnership with Nestlé Health Science. A change in the product lineup or distribution terms could shift the direction of brand sales.

The company has set a 2030 target above KRW 100 billion, but the detailed partnership terms need to be checked through disclosures.

Overseas subsidiary and asset impairment

The Chinese subsidiary posted an operating loss of about KRW 6.0 billion in 2023, and the company decided to sell it at the end of 2024. One-off gains or losses and asset impairments could arise around the completion of the sale.

In 2024, a property impairment loss lowered net income, so asset valuation results feed directly into reported earnings.

Possible revisions to preliminary results

Third-quarter 2026 results were released as preliminary figures, which the company noted could change after the external auditor's review. Any gap between preliminary and final figures could affect how the profit streak is read. Full-year confirmed results will be shown in the 2026 annual report.

11

What to watch next

  1. Early 2027 (date not yet set)

    Preliminary full-year 2026 results. Since net income attributable to controlling shareholders was only KRW 253 million in 2025, the key check is whether the quarterly profit streak carried through to full-year earnings.

  2. End of March 2027

    Filing of the 2026 annual report. The report is generally due within 90 days after fiscal year-end, and it will confirm fourth-quarter and full-year 2026 figures.

  3. Late April 2027 (based on past first-quarter release timing)

    First-quarter 2027 results. The key checks are whether profitability continues from the first quarter of 2026 and whether operating margin holds near the second-quarter 2026 level.

  4. By 2030 (medium- to long-term target)

    Progress toward the target of more than KRW 100 billion in health functional food distribution sales. The check is how fast sales, which started from KRW 20.7 billion in 2024, grow each year.

12

Overall view

Hyundai Bioland's revenue rose for three straight years from 2023 through 2025 to KRW 130.5 billion, but net income attributable to controlling shareholders declined after 2024 to KRW 253 million in 2025.

Operating profit and net income attributable to controlling shareholders were both positive in each quarter from the first quarter through the third quarter of 2026, and net income attributable to controlling shareholders over the latest four quarters totals KRW 13.6 billion.

Strengths include the return to profit, a debt ratio that fell to 22.6% at the end of 2025, and operating cash flow of KRW 19.5 billion. Weaknesses include year-to-year swings in operating margin, the sharp drop in 2025 net income, and the breakeven burden of the brand business.

Growth is spread across cosmetic ingredients, medical devices and branded health food distribution, where a target above KRW 100 billion by 2030 has been set. Valuation should be read alongside the fact that the share price is below 1 times net asset value and the recent quarterly earnings trend.

Fourth-quarter and full-year 2026 results have not yet been released in regular reports, and the operating margin and brand sales trend in the next regular report are the checkpoints.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. kormedi.com
  3. finance-scope.com
  4. ehyundai.com
  5. topdaily.kr
  6. jasoseol.com
  7. etoday.co.kr
  8. m.ddaily.co.kr
  9. m.news.nate.com
  10. vegannews.co.kr
  11. hyundaibioland.irpage.co.kr
  12. comp.wisereport.co.kr
  13. invest.kiwoom.com
  14. m.irgo.co.kr
  15. investing.com
  16. wcomp.fnguide.com
  17. google.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis